Fig. 1: Persisting/acquired non-DTA mutations at CMR confer inferior survival in AML with mutated NPM1.
From: Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
A Mutation frequencies of AML associated genes in diagnostic and complete molecular remission (CMR) samples. The percentage of each gene alteration among all the mutations per timepoint is depicted. *FLT3-ITD mutations were detected by gene scan. B Survival analysis of patients with NPM1mut AML stratified by persistence or acquisition of DTA vs non-DTA mutations at CMR. Kaplan–Meier plots depicting event-free survival (EFS left panel) and overall survival (OS right panel) of NPM1mut AML patients based on the combination of persistency and acquisition of non-DTA mutations at CMR. Patients showing non-DTA hits at CMR have a worse prognosis than those who do not. P values were calculated with the log-rank test and p values for pairwise comparisons are given.
